Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan

Pediatric Blood and Cancer

Volumn 46, Issue 3, 2006, Pages 285-291

  Kaneko, Yasuhiko ^a   Kobayashi, Hirofumi ^a   Watanabe, Naoki ^a   Tomioka, Nobumoto ^a,b   Nakagawara, Akira ^b  

^a SAITAMA CANCER CENTER   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Constitution of chromosome 1; Mass screening; Neuroblastoma; Ploidy

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; CYCLOPHOSPHAMIDE; DNA; HOMOVANILLIC ACID; VANILMANDELIC ACID; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CATECHOLAMINE URINE LEVEL; CHILDHOOD CANCER; CHROMOSOME 1; CYTOGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFANT; JAPAN; MAJOR CLINICAL STUDY; MASS SCREENING; NEUROBLASTOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANEUPLOIDY; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; JAPAN; MALE; MASS SCREENING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 32044446271     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20496     Document Type: Article

References (19)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Pediatric oncology. 3rd edn. Philadelphia: PA, Lippincott, Inc.; 1997. pp 761-197.
2. Sawada T, Hirayama M, Nakata T, et al. Mass screening for neuroblastoma in infants in Japan. Lancet 1984;2:271-273.
3. Wood WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346:1041-1046.
4. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047-1053.
5. Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: Cohort study in seven prefectures in Japan. J Clin Oncol 2002;20:1209-1214.
6. Hayashi K, Fujita T, Katanoda K, et al. Effectiveness of mass-screening program on neuroblastoma mortality in 1995-2000 birth cohort of Japan: Nationwide neuroblastoma mortality study. Presented at 11th conference on advances in neuroblastoma research, Genoa, Italy, June In abstract p93. 2004; 16-19.
7. Kaneko Y, Kanda N, Maseki N, et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: A chromosome and N-myc amplification study. J Clin Oncol 1990;8:2005-2013.
8. Kaneko Y, Kobayashi H, Maseki N, et al. Disomy 1 with terminal 1p deletion was frequent in mass screening-negative/late-presenting neuroblastomas in young children, but not in mass screening-positive neuroblastomas in infants. Int J Cancer 1999;80:54-59.
9. Report of the committee on mass screening program for neuroblastoma in Japan. Jpn J Pediatr Oncol 2003;403:286-298.
10. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
11. Sawaguchi S, Kaneko M, Uchino J, et al. Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. Cancer 1990;66:1879-1887.
12. Lastowska M, Cullinane C, Variend S, et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001;19:3080-3090.
13. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nature Rev 2003;3:203-216.
14. Kerbl R, Urban CE, Ambros LM, et al. Neuroblastoma mass screening in late infancy: Insights into the biology of neuroblastic tumors. J Clin Oncol 2003;21:4228-4234.
15. Ambros PF, Ambros IM, Kerbl R, et al. Intraumoural heterogeneity of 1p deletion and MYCN amplification in neuroblastomas. Med Pediatr Oncol 2001;36:1-4.
16. Kaneko Y, Knudson AG. Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer 2000;29:89-95.
17. Caron H, Van Sluis P, De Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-230.
18. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: A pediatric oncology group study. J Natl Cancer Inst 1997;89:373-380.
19. Ladenstein R, Ambros IM, Potschger U, et al. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol 2001;36:83-92.